Rejuvenant

**Rejuvenants** are biochemical and nanotechnological medicines that are used for the "rejuvenation" of organic tissues found within the human body, thus preventing senescence. They are almost solely used by Amritas: individuals who possess enough wealth to routinely administer them and extend their life.

The mechanism of action for rejuvenants namely works upon the extension of human chromosomal telomeres through indirect protein and direct nanomachine actions, extending cellular function and therefore human lives for a large period of time. Such action is often done in addition to the repair of previously damaged cytological structures, reversion of accumulated genetic mutations, and repulsion of prion formation and proliferation. However, no current biomedical technology has been uncovered that can lead to an "infinite organic immortality", with most rejuvenation therapies only working to extend the human lifespan to around three centuries as a result of the exponentially increasing psychological risks imposed by artificially extended lifespans.

The most commonly used brand of rejuvenant medicine is known as **Ambrosia**, administered by Tachi Pharmaceuticals of the Stapleford Group; this medicine and its employed rejuvenant therapy usually costs 1 billion notes per session *in vivo*.

## Mechanism of action

### Artificial telomere extension

#### In vivo

*In vivo artificial telomere extension,* administered after birth, is the main method of extending telomeres due to its relative cost compared *in vitro* extension offered by biomedical corporations. This is done through a combination of nanomachines and artificial messenger RNA molecules that aid in the extension of human telomere nucleotide sequences in accordance to the age extension desired. Usually done incrementally, it is combined with other functions as a multilateral process of ensuring artificial immortality, but by itself does not protect against aging processes.

#### In vitro

*In vitro artificial telomere extension,* administered before birth, is another method of extending telomeres, and works by the actions of nanomachines editing the starting telomere caps of human zygotes to a predefined nucleotide length that corresponds with the desired age extension. Since this procedure is hypothetically done only *once* (unless errors arise), it is also the most expensive procedure, artificially inflated to be at around 10.5 billion notes by corporations such as VISTA Biotechnologies per human zygote with an ensured progeny of only one human child—the reasoning for this stemming from the inability to guarantee a lifelong customer for *in vivo* therapies for telomere extensions. In vitro extensions confer benefits that are included alongside *in vivo* therapies, including prion defense, cytological or genetic repair mechanisms, and telomere cap replenishment and/or repair; these are done through a robust life-long medical plan activated upon payment of the initial sum.

### Cytological and genetic repair, editing

A key function of rejuvenants includes their ability to repair cytological and genetic damage of spontaneous or congenital origin, and thus aid in anti-aging properties. This includes correcting accumulated genetic mutations identified by prior tests and the restoration of function and/or structure to various cellular organelles. The subtherapy is especially important in the continued function of cells that do not undergo further cellular division with age, such as neurocytes, or in the restoration of structures that generally do not regenerate, such as the nephrons of the kidneys.

#### Complete Somatic and Gametic Genetic Conversion (CSGGC)

*Complete Somatic and Gametic Genetic Conversion therapies,* or CSGGC therapies, are the most expensive form of rejuvenant therapy to exist, costing around 200 billion notes per person and increasing exponentially in price with the biomass of said individual. CSGGC therapies involve the complete rewrite of one's genetic code for all existent somatic and gametic cells, and involves the work of a massive amount of nanomachines that inevitably perforate the (on average) nearly forty trillion cells existent in the human body.

CSGGCs are administered on individuals who did not go through *zygotic genetic conversion* (ZGC, costing a quarter as much in most cases), and can technically be administered as many times as the individual desires. Due to editing the entirety of the present human genome and subsequently affecting the epigenome and proteome, and due to the combined volume of nanomachines used and risk involved, it is only utilized by the most wealthy and powerful in the Coalition to remove any accumulated genetic mutations or to incur new phenotypic variations through novel endocrinal expressions and chromosomal configurations, such as changing one's biological sex. Macro-scale conflictions from CSGGCs are usually corrected through subsequent macroscale surgeries.

### Prion defense

Rejuvenant therapies and medications also include *prion defenses* due to the threat of misfolded proteins arising from spontaneous or congenital sources increasing with the length of one's lifespan. These defenses mainly come in the form of nanomachines, which detect and re-fold prion particles back into their natural tertiary conformations, or alternatively destroy prion particles through applied hydrolysis. The cost of manufacturing errorless nanomachines in numbers sufficient enough to prevent prion formation (or neutralizing present prions), in conjunction with other cytological and genetic repairs throughout the human body confers a large percentage of the cost of rejuvenants.